Structure Therapeutics Inc. Operating Expenses
Structure Therapeutics Inc. (GPCR) reported Operating Expenses of $118.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Structure Therapeutics Inc. operating expenses for the quarter ending 2026-06-30 was $118.63M, a 68.39% increase year-over-year.
- Structure Therapeutics Inc. operating expenses for the quarter ending 2026-03-31 was $89.38M, a 58.72% increase year-over-year.
- Structure Therapeutics Inc. operating expenses for the quarter ending 2025-12-31 was -$23.99M, a 150.97% decline year-over-year.
- Structure Therapeutics Inc. operating expenses for the quarter ending 2025-09-30 was $73.79M, a 60.98% increase year-over-year.
- Structure Therapeutics Inc. operating expenses for fiscal 2025 was $176.56M, a 11.59% increase from fiscal 2024.
- Structure Therapeutics Inc. operating expenses for fiscal 2024 was $158.23M, a 53.96% increase from fiscal 2023.
- Structure Therapeutics Inc. operating expenses for fiscal 2023 was $102.78M, a 95.53% increase from fiscal 2022.
- Structure Therapeutics Inc. operating expenses for fiscal 2022 was $52.56M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $118.63M 10-Q · filed 2026-08-06 | $208.01M 10-Q · filed 2026-08-06 | $184.02M derived: sum of 3 quarters · filed 2026-08-06 | $257.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $89.38M 10-Q · filed 2026-05-07 | $65.39M derived: sum of 2 quarters · filed 2026-05-07 | $139.18M derived: sum of 3 quarters · filed 2026-05-07 | $209.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$23.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $49.80M derived: sum of 2 quarters · filed 2026-02-26 | $120.25M derived: sum of 3 quarters · filed 2026-08-06 | $176.56M 10-K · filed 2026-02-26 |
| 2025-09-30 | $73.79M 10-Q · filed 2025-11-06 | $144.24M derived: sum of 2 quarters · filed 2026-08-06 | $200.55M 10-Q · filed 2025-11-06 | $247.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $70.45M 10-Q · filed 2026-08-06 | $126.76M 10-Q · filed 2026-08-06 | $173.82M derived: sum of 3 quarters · filed 2026-08-06 | $219.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $56.31M 10-Q · filed 2026-05-07 | $103.37M derived: sum of 2 quarters · filed 2026-05-07 | $149.21M derived: sum of 3 quarters · filed 2026-05-07 | $182.52M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $47.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $92.90M derived: sum of 2 quarters · filed 2026-02-26 | $126.21M derived: sum of 3 quarters · filed 2026-02-26 | $158.23M 10-K · filed 2026-02-26 |
| 2024-09-30 | $45.84M 10-Q · filed 2025-11-06 | $79.15M derived: sum of 2 quarters · filed 2025-11-06 | $111.17M 10-Q · filed 2025-11-06 | $142.16M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $33.32M 10-Q · filed 2025-08-06 | $65.33M 10-Q · filed 2025-08-06 | $96.33M derived: sum of 3 quarters · filed 2026-02-26 | $122.47M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $32.02M 10-Q · filed 2025-05-08 | $63.01M derived: sum of 2 quarters · filed 2026-02-26 | $89.15M derived: sum of 3 quarters · filed 2026-02-26 | $115.14M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $30.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $57.14M derived: sum of 2 quarters · filed 2026-02-26 | $83.13M derived: sum of 3 quarters · filed 2026-02-26 | $102.78M 10-K · filed 2026-02-26 |
| 2023-09-30 | $26.14M 10-Q · filed 2024-11-13 | $52.13M derived: sum of 2 quarters · filed 2024-11-13 | $71.78M 10-Q · filed 2024-11-13 | $84.74M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $25.99M 10-Q · filed 2024-08-08 | $45.64M 10-Q · filed 2024-08-08 | $58.59M derived: sum of 3 quarters · filed 2024-08-08 | $71.28M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $19.65M 10-Q · filed 2024-05-09 | $32.60M derived: sum of 2 quarters · filed 2024-05-09 | $45.30M derived: sum of 3 quarters · filed 2024-05-09 | $59.26M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $12.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $25.65M derived: sum of 2 quarters · filed 2024-03-08 | $39.61M derived: sum of 3 quarters · filed 2024-03-08 | $52.56M 10-K · filed 2024-03-08 |
| 2022-09-30 | $12.69M 10-Q · filed 2023-11-17 | $26.65M derived: sum of 2 quarters · filed 2023-11-17 | $39.60M 10-Q · filed 2023-11-17 | |
| 2022-06-30 | $13.96M 10-Q/A · filed 2023-11-17 | $26.91M 10-Q/A · filed 2023-11-17 | ||
| 2022-03-31 | $12.95M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |